Connect with us


Delta plus: Scientists say too early to tell risk of Covid-19 variant.



The Delta plus type, also known as AY.1, spreads more rapidly, attaches more easily to lung cells, and is potentially resistant to monoclonal antibody therapy, according to India’s health ministry. It’s linked to the Delta, which is suspected to be the source of India’s catastrophic second wave of illnesses this summer. 

The Delta plus strain of the flu has been found in roughly 40 samples from six regions across three Indian states: Maharashtra, Kerala, and Madhya Pradesh, according to India’s health ministry. At least 16 of these samples were discovered in Maharashtra, one of the pandemic’s worst-affected states. Delta plus has also been discovered in the United States, the United Kingdom, Portugal, Switzerland, Japan, Poland, Nepal, and Russia. In comparison to the original extremely contagious Delta strain, Delta plus has been detected in nine other countries: the United States, the United Kingdom, Portugal, Switzerland, Japan, Poland, Nepal, Russia, and China.

A new strain of Ebola virus has been discovered, although it is unclear whether it poses a public health hazard. The Department of Health and Human Services is keeping an eye on the sickness for signs of a mutation that might make it more infectious or harmful. The virus is not harmful to humans, hence there is no risk to the public’s health.

Leading virologists have questioned whether Delta plus should be classified as a concern variation. They claim that there is now no evidence that the variant was more infectious or caused more severe disease than other variants. “There is no data to support the variety of worry claims,” said Dr Gagandeep Kang, the first Indian woman to be elected Fellow of the Royal Society of London. 

India requires additional information to identify whether the variant is neutralised by antibodies produced by current vaccines or by infection with a different coronavirus variant. More information is needed on the increased transmissibility, diagnostic failures (regular tests failing to detect the variant), and whether the variant is causing more severe disease.

The Delta plus variation possesses an extra mutation on the coronavirus spike known as K417N, which was first discovered in the Beta and Gamma versions in South Africa and Brazil, respectively. According to a virologist at Louisiana State University Health Sciences Center in Shreveport, there is no reason to suppose this is any more hazardous than the original Delta.

Kamil, Dr. “I’d retain my cool. I don’t believe India, or anyone else in the globe, has provided or amassed enough evidence to separate the risk of the so-called Delta plus version from the original Delta variant.” “All lineages of the Delta variation are variants,” said Dr. Anurag Agarwal, director of the CSIR-Institute of Genomics and Integrative Biology (IGIB) in Delhi.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


The right pricing will be crucial for the launch of Zydus Cadila’s vaccine.




The destiny of Zydus Cadila’s Covid vaccine is in doubt, as the vaccine’s price appears to be delaying its introduction into the vaccination program. The business has received emergency use authorization from the FDA to inject its Covid vaccine, ZyCoV-D, to children aged 12 to 18.

Zydus Cadila, located in Ahmedabad, has imported the pharmaJet, a needle-free applicator for painless intradermal vaccine delivery. 

Each jet is responsible for delivering a specific amount of vaccination. 

As a result, a single dose is split into two shots, one for each arm. “It’s an expensive device and hence jacks up the overall price,” a government official said.

Around 20,000 dosages can be administered with the jet injector.

The government has been purchasing Covaxin at 225 per dosage and Covishield, another Covid vaccine developed in India, at 215 per dose.

The price of the Zydus Cadila vaccine, according to Health Secretary Rajesh Bhushan, will be significantly more than that of existing vaccines.

Continue Reading


The next wave of healthcare innovation




Healthcare industry is currently one of the leaders in this race of startups. From Practo to Netmeds, India has seen companies go progress exponentially.  

Launched in March 2021, Know Your Prescription (KYP) is a patient-centric product that explains the prescription and addresses general, treatment-related queries in English, Hindi, Punjabi, Bengali, and Malayalam.   

 KYP assists in the understanding of medical prescriptions. All a patient has to do is visit the AI-enabled portal (QR code), which, after proper diligence, connects them to a WhatsApp number. They are paired with pharmacists or retired medical professionals in order to fully comprehend what their prescription entails. This reduces medication errors while also improving patient compliance and adherence.  

 The product is specially designed keeping the general population in mind, and the startup is eyeing a pan-India audience “with a major focus on Tier II and III cities”.

 The Delhi-based startup, with a team size of 12, has also signed a three-year contract with Centre for Sight, which is one of the largest chains in India with more than 47 centres.  

 It hopes to develop an app soon that will allow users to submit their questions, as well as onboard   qualified pharmacists and doctors to assist them.  

 As of now, KYP has over 5,000 unique paid clients. By Diwali, SiCureMi intends to implement a Rs 299   yearly membership scheme. Users will be able to upload prescriptions an unlimited number of   times as a result of this.

Continue Reading


The pandemic may take the sparkle out of India’s Diwali spending in 2021




Diwali, the Festival of Lights, is one of the most widely celebrated festivals in India. Every state has its puja and rituals to bring in this colorful festival.

Every year, people tend to spend a lot of money during this festive season. From crackers to sweets and dresses, a lot of money flows through businesses in the festive season. 

However, after the pandemic, things have changed and Diwali spending saw a huge downfall in 2020. 

Diwali spending not expected to recover in 2021

In 2019, Diwali was one of the fastest-growing business periods. Over 43% of Indians spent tons of money during this festive period. However, COVID-19 struck hard in 2020 leading India to enter into a pandemic season. With the whole country on lockdown and cases increasing, the big question was how would the festive period be treated in 2020.

To no surprise, Diwali 2020 reached a major low leading a lot of businesses to reach a loss. Only 17% claimed to have been eager to spend during the festival season in 2020. 

However, as Diwali 2021 approaches and COVID-19 has been accepted as the new normal, the question arises again, Will Diwali spending fully recover this year? The answer is there will be a small recovery and growth, but not a complete one. According to a survey carried out by YouGov, Diwali spending was calculated and it was shown that it rose by 10 points this year, with 91% of urban Indians saying they would be spending more this year.

While the festive season appears and everyone looks forward to celebrating, it is important to keep in mind that the pandemic is still around us and we need to ensure all safety measures are undertaken in this fight against COVID-19. 

Continue Reading